First in Human of Single and Multiple Doses of MOR106

Summary

This is a randomized, double-blind, placebo-controlled, dose-escalation, phase I study for the assessment of safety, tolerability and pharmacokinetics of single ascending doses of MOR106 in healthy male subjects and multiple ascending doses in subjects with moderate to severe atopic dermatitis.

Timeline

Start

2016-04

Primary completion

2017-08-01

Completion

2017-08-01

Drugs

Indications